Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinosarcoma × pazopanib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 22 Sarcoma 14 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 8 Breast Neoplasms 8 Ovarian Neoplasms 6 Recurrence 5 Neoplasms 5 Melanoma 4 Leiomyosarcoma 4 Urinary Bladder Neoplasms 3 Neuroendocrine Tumors 3 Lung Neoplasms 3 Liposarcoma 3 Hemangiosarcoma 3 Glioblastoma 3 Gastrointestinal Stromal Tumors 3 Fallopian Tube Neoplasms 3 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma, Synovial 2 Sarcoma, Alveolar Soft Part 2 Rhabdomyosarcoma 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Kidney Neoplasms 2 Gliosarcoma 2 Clear-cell metastatic renal cell carcinoma 2

Interventions

Nivolumab 5 Paclitaxel 3 olaparib 2 Specimen Handling 2 Magnetic Resonance Spectroscopy 2 rucaparib 1 pazopanib 1 pamiparib 1 durvalumab 1 ceralasertib 1 cediranib 1 cabozantinib 1 apatinib 1 Trabectedin 1 Ipilimumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 CTLA-4 Antigen 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02203760 2024-11-15

PazoDoble

North Eastern German Society of Gynaecological Oncology

Phase 2 Active not recruiting

Carcinosarcoma, Leiomyosarcoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡